{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.336","value":"-2.32"}]}],"title":"Retreatment 1 (n = 304)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.302","value":"-2.77"}]}],"title":"Retreatment 2 (n = 258)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.388","value":"-3.01"}]}],"title":"Retreatment 3 (n = 227)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.537","value":"-3.05"}]}],"title":"Retreatment 4 (n = 168)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.536","value":"-3.15"}]}],"title":"Retreatment 5 (n = 132)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.540","value":"-2.96"}]}],"title":"Retreatment 6 (n = 87)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"335"}],"units":"Participants"}],"description":"The DAS28 is an index for measuring disease activity in rheumatic arthritis and includes swollen and tender joint counts, erythrocyte sedimentation rate (ESR), and general health (GH) status. The index is calculated with the following formula: DAS28 = (0.56 × √(TJC28)) + (0.28 × √(SJC28)) + (0.7 × log(ESR)) + (0.014 × GH), where TJC28 = tender joint count and SJC28 = swollen joint count, each on 28 joints. GH = a patient's global assessment of disease activity in the previous 24 hours on a 100 mm visual analog scale (left end = no disease activity \\[symptom-free and no arthritis symptoms\\], right end = maximum disease activity \\[maximum arthritis disease activity\\]). When ESR equaled 0 mm/hr, it was set to 1 mm/hr. The DAS28 scale ranges from 0 to 10, where a higher score represents higher disease activity. A negative change score indicates improvement. The first retreatment may have occurred in the precursor study WA17042.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received rituximab 1 g intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid ≥ 5 mg/week or equivalent, given as either a single dose or as divided daily doses.","id":"OG000","title":"Rituximab"}],"paramType":"MEAN","populationDescription":"Intent-to-treat population: All participants who received any part of an infusion of study medication in study WA17531.","reportingStatus":"POSTED","timeFrame":"Baseline to the end of the retreatment period (up to 7 years, 6 months)","title":"Change From Baseline in the Disease Activity Score 28 (DAS28)","type":"SECONDARY","unitOfMeasure":"Units on a scale"}